Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2002-4-4
pubmed:abstractText
Neurofibrillary tangles, one of the pathologic hallmarks of Alzheimer's disease (AD), are composed of abnormally polymerized tau protein. The hyperphosphorylation of tau alters its normal cellular function and is thought to promote the formation of neurofibrillary tangles. Growing evidence suggests that cyclin-dependent kinase 5 (cdk5) plays a role in tau phosphorylation, but the function of the enzyme in tangle formation remains uncertain. In AD, cdk5 is constitutively activated by p25, a highly stable, 25kD protein thought to be increased in the AD brain. To test the hypothesis that p25/cdk5 interactions promote neurofibrillary pathology, we created transgenic mouse lines that overexpress the human p25 protein specifically in neurons. Mice with high transgenic p25 expression have augmented cdk5 activity and develop severe hindlimb semiparalysis and mild forelimb dyskinesia beginning at approximately 3 months of age. Immunohistochemical and ultrastructural analyses showed widespread axonal degeneration with focal accumulation of tau in various regions of the brain and, to a lesser extent, the spinal cord. However, there was no evidence of neurofibrillary tangles in neuronal somata or axons, nor were paired helical filaments evident ultrastructurally. These studies confirm that p25 overexpression can lead to tau abnormalities and axonal degeneration in vivo but do not support the hypothesis that p25-related induction of cdk5 is a primary event in the genesis of neurofibrillary tangles.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0021-9967
pubmed:author
pubmed:copyrightInfo
Copyright 2002 Wiley-Liss, Inc.
pubmed:issnType
Print
pubmed:day
6
pubmed:volume
446
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
257-66
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:11932941-Animals, pubmed-meshheading:11932941-Axons, pubmed-meshheading:11932941-Blotting, Western, pubmed-meshheading:11932941-Cyclin-Dependent Kinase 5, pubmed-meshheading:11932941-Cyclin-Dependent Kinases, pubmed-meshheading:11932941-Dyskinesias, pubmed-meshheading:11932941-Immunohistochemistry, pubmed-meshheading:11932941-Mice, pubmed-meshheading:11932941-Mice, Transgenic, pubmed-meshheading:11932941-Microscopy, Electron, pubmed-meshheading:11932941-Muscle, Skeletal, pubmed-meshheading:11932941-Nerve Degeneration, pubmed-meshheading:11932941-Nerve Tissue Proteins, pubmed-meshheading:11932941-Neurofibrillary Tangles, pubmed-meshheading:11932941-Peripheral Nerves, pubmed-meshheading:11932941-Platelet-Derived Growth Factor, pubmed-meshheading:11932941-Promoter Regions, Genetic, pubmed-meshheading:11932941-Sciatic Nerve, pubmed-meshheading:11932941-Transgenes, pubmed-meshheading:11932941-tau Proteins
pubmed:year
2002
pubmed:articleTitle
Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice.
pubmed:affiliation
CNS Pharmacology, Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105, USA. feng.bian@pfizer.com
pubmed:publicationType
Journal Article